For research use only
| Cat No. | ABC-X0326C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human HRAS (G13R) BAF3 Cell Line enables research into HRAS-driven signal transduction, oncogenic potential, and drug targeting in hematologic cancers.
Human HRAS (G13R) BAF3 Overexpression Cell Line is engineered from Ba/F3 cells by stable lentiviral transduction of human HRAS harboring the G13R mutation. Cells are maintained under low passage (<P20) and validated for expression using qRT-PCR. Target HRAS is a key GTPase in the RAS/RAF/MEK/ERK pathway. The G13R mutation renders HRAS constitutively active, promoting oncogenic signaling. It is associated with cancers such as bladder carcinoma and thyroid cancer. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.
| Species | Human |
| Cat.No | ABC-X0326C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell model is suited for dissecting RAS-dependent oncogenesis and for evaluating the efficacy of novel RAS pathway inhibitors in preclinical settings.